Kiniksa Pharmaceuticals International, plc 2026 Q1 - Results - Earnings Call Presentation

Corroborated by 2 sources from 2 publishers

globalhealth5h ago

TL;DR

Reports differ across sources; according to finance.yahoo.com, kiniksa Pharmaceuticals International (NASDAQ:KNSA) reported first-quarter 2026 results and provided updates on commercial execution for ARCALYST and progress across its clinical pipeline, including KPL-387 and KPL-1161.

Sources